Tuberculosis (TB) bacteria can be transmitted when someone with active TB in their lungs coughs or sneezes. People whose immune system is keeping TB under control (latent TB) can take a course of medication known as isoniazid preventive therapy in order to reduce their risk of developing active TB disease. Research is ongoing into a vaccine that could be given to people with latent TB.

TB transmission and prevention: latest news

TB transmission and prevention resources

  • Tuberculosis

    Tuberculosis (TB) is an infection that usually affects the lungs.It can be very serious, particularly for people living with HIV who have a low CD4 count.TB can...

    From: Factsheets

    Information level Level 2
  • TB and HIV

    If HIV has weakened your immune system, you are more vulnerable to tuberculosis (TB). TB is an infection caused by bacteria. It is a serious...

    From: The basics

    Information level Level 1
  • How TB is passed on

    The bacteria that cause tuberculosis (TB) can sometimes pass from one person to another through the air. TB bacteria can sometimes be spread through the...

    From: The basics

    Information level Level 1

TB transmission and prevention features

TB transmission and prevention in your own words

TB transmission and prevention news from aidsmap

More news

TB transmission and prevention news selected from other sources

  • 49th Union World Conference on Lung Health: Integrating HIV treatment and TB preventative therapy greatly improves IPT adherence

    When tuberculosis preventive therapy is delivered with HIV treatment services and patients get a choice in where they access treatment, completion of tuberculosis preventive therapy rises, helping to ensure people living with HIV stay healthy, researchers said here. This model of prevention should be scaled up in TB-HIV high burden settings, researchers said.

    05 November 2018 | Science Speaks
  • 49th Union World Conference on Lung Health: First promising TB vaccine candidate in 100 years needs more resources, researchers say

    It's taken 100 years to see any progress in the development of a vaccine to prevent tuberculosis, a disease that kills 4,000 every day, Lucica Ditiu, executive director of the Stop TB Partnership said here. Even now, it remains uncertain that a new vaccine will see the light of day, she said, as more funding has yet to be secured for larger-scale trials to confirm the promising results of the M72 vaccine candidate.

    29 October 2018 | Science Speaks
  • GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study

    Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection[2] in an ongoing phase IIb clinical trial testing. These primary results published in the New England Journal of Medicine after two years of trial demonstrate an overall vaccine efficacy of 54%, with varied response rates observed in different demographic sub-groups.

    26 September 2018 | Aeras
  • TB Treatment May Leave Some Patients Contagious

    The World Health Organization’s dosage guidelines for two leading tuberculosis medications may be far too low for patients with H.I.V., allowing them to remain contagious for longer than necessary, a new study has found.

    09 April 2018 | New York Times
  • TB vaccine trial results offer potential for BCG Revaccination, hope for subunit vaccines

    Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents. In a prevention-of-infection Phase 2 trial conducted in South Africa, revaccination with the Bacille Calmette-Guerin (BCG) vaccine significantly reduced sustained TB infections in adolescents. An experimental vaccine candidate, H4:IC31, also reduced sustained infections, although not at statistically significant levels.

    19 February 2018 | Eurekalert Medicine & Health
  • The 2017 Pipeline Report

    Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

    19 July 2017 | Treatment Action Group
  • Person-to-person contact may cause most drug-resistant TB cases

    The worst form of drug-resistant tuberculosis isn't just arising from inadequate treatment, it's mostly being spread from person to person, according to a new study of hundreds of cases in South Africa.

    23 January 2017 | Reuters
  • Latent TB high in India's healthcare workers

    While India continues to have the highest burden of tuberculosis in the world, about 23 per cent of the 8.7 million global incidences, a study reports nearly half of its healthcare workers taking care of TB patients also suffer from latent tuberculosis.

    17 October 2016 | SciDevNet
  • TB drugs may be disrupted by botanical supplement, MU researchers find

    MU researchers, working with scientists in Africa, discovered that a widely used African botanical supplement called Sutherlandia — traditionally taken to prevent or treat symptoms of infections — may actually disrupt the effectiveness of a common anti-tuberculosis drug, isoniazid.

    11 October 2016 | Kansas City Star
  • Zimbabwe study sees TB go down as HIV treatment coverage goes up

    As the numbers of people accessing HIV treatment went up in Zimbabwe, the numbers of reported tuberculosis cases were cut nearly in half.

    06 October 2016 | Science Speaks
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.